Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.PharmacoEconomics · 2015
   Article
2. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.Journal of thrombosis and thrombolysis · 2014
   Article
3. Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?Cardiology research and practice · 2011
   Article
4. Risk factor management to prevent first stroke.Neurologic clinics · 2008
   Review
5. Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study.BMC public health · 2007
   Article
6. Rehospitalization and survival for stroke patients in managed care and traditional Medicare plans.Medical care · 2005
   Article
7. Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes?Heart (British Cardiac Society) · 2005
   Article
8. Prevention of cardiovascular events in elderly people.Drugs & aging · 2005
   Review
9. Valsartan in acute myocardial infarction trial.Current cardiology reports · 2004
   Article
10. Atrial fibrillation in a primary care practice: prevalence and management.BMC family practice · 2002
    Article

Corrections and comments

• Comment on
  Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators.1999
• Comment on
  Use of antithrombotic measures for stroke prevention in atrial fibrillation.1999

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as